In patients with HNSCC undergoing curative-intent surgery and heterogeneous adjuvant therapy, TP53 mutations were associated with reduced survival, independent of pathologic nodal stage or primary tumor site [161]. The gene discussed is TP53; the disease is head and neck squamous cell carcinoma.